PA
PTCT icon

Parallel Advisors’s PTC Therapeutics PTCT Stock Holding History

Parallel Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.04K Buy
74
+31
+72% +$2.24K ﹤0.01% 3146
2026
Q1 		$2.93K Buy
43
+5
+13% +$354 ﹤0.01% 3238
2025
Q4 		$2.89K Hold
38
– – ﹤0.01% 3028
2025
Q3 		$2.33K Hold
38
– – ﹤0.01% 3008
2025
Q2 		$1.86K Hold
38
– – ﹤0.01% 3056
2025
Q1 		$1.94K Hold
38
– – ﹤0.01% 2986
2024
Q4 		$1.72K Buy
38
+8
+27% +$342 ﹤0.01% 3009
2024
Q3 		$1.11K Hold
30
– – ﹤0.01% 3006
2024
Q2 		$917 Buy
+30
New +$972 ﹤0.01% 2982
2022
Q2 		– Sell
-110
Closed -$4K – 3281
2022
Q1 		$4K Sell
110
-21
-16% -$809 ﹤0.01% 2397
2021
Q4 		$5K Sell
131
-7
-5% -$268 ﹤0.01% 2417
2021
Q3 		$5K Sell
138
-5
-3% -$205 ﹤0.01% 2377
2021
Q2 		$6K Buy
143
+92
+180% +$3.94K ﹤0.01% 2243
2021
Q1 		$2K Buy
+51
New +$3.03K ﹤0.01% 2500
2018
Q3 		– Sell
-500
Closed -$16K – 2279
2018
Q2 		$16K Buy
+500
New +$15.6K ﹤0.01% 1149

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Parallel Advisors's PTCT Position: Q2 2026 in Review

Parallel Advisors increased its PTC Therapeutics (PTCT) stake by 72% in Q2 2026, buying an estimated $2.24K and bringing the position to 74 shares worth $6.04K. The position accounts for ﹤0.01% of the portfolio, ranked #3146.

Parallel Advisors first reported a position in PTCT in Q2 2018 and has held it in 15 quarters since. The position peaked at $16K in Q2 2018. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Parallel Advisors held 74 shares of PTC Therapeutics worth $6.04K as of Q2 2026.
  • Parallel Advisors bought 31 PTC Therapeutics shares in Q2 2026, an estimated $2.24K.
  • PTC Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3146 holding.
  • Parallel Advisors first reported a position in PTC Therapeutics in Q2 2018 and has held it in 15 quarters since.
  • Parallel Advisors's PTC Therapeutics position peaked at $16K in Q2 2018.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.